All In Biotech

Drug Trial Radar · NCT04275518

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

A Phase Ib Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of APG-115 as a Single Agent or in Combination With Azacitidine or Cytarabine in Patients With Relapse/Refractory AML and Relapsed/Progressed High/Very High Risk MDS

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

102

Planned (sponsor's estimate)

Start

Jul 6, 2020

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
Collaborators
Suzhou Yasheng Pharmaceutical Co., Ltd.
First posted
Feb 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled proliferation of malignant clonal hematopoietic stem cells that accumulate as immature, undifferentiated cells (blasts) in the bone marrow and circulation. APG-115 is a potent and orally active small-molecule MDM2 inhibitor, it binds to MDM2 protein and shows potent cell growth inhibitory activity in vitro with low nanomolar potencies in a subset of human cancer cell lines. APG-115 has demonstrated its strong antitumor activities with either daily or less frequent dosing-schedules in the acute leukemia xenograft models. This is a phase 1b, open-label, three-stages study that will initially evaluate the safety and PK/PD profile of APG-115 as a single agent, followed by a combination of APG-115 + azacytidine or cytarabine in R/R AML or MDS subjects. Patients will continue treatment for maximally 6 cycles or until progression of disease or unacceptable toxicity is observed or administrative discontinuation whichever occurs first. Patients who continue to be benefit after 6 cycles' treatment will receive additional cycles of treatment until progression of disease, unacceptable toxicity is observed or administrative discontinuation. (As long as it is proven safe).

Conditions

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndromes (MDS)

Interventions

  • APG-115Drug

    APG-115 orally once daily from Days 1 to 7 every 28 days.

  • AzacitidineDrug

    75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)

  • CytarabineDrug

    1g/m\^2 IV QD on Days 3-7 (28-day cycle)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT)Time frame: From day 1 to the end of cycle 1 (each cycle is 28 days).

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Peking University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Guangzhou panyu central hospital

    Guangzhou, Guangdong, China · Recruiting

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Henan Provincial Oncology Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital medical college Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Recruiting

  • The First Affilated Hospital of Ganzhou Medical University

    Suzhou, Jiangsu, China · Not yet recruiting

  • The First affiliated hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Shanghai Jiao Tong University school of medicine Ruijing Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Sixth people's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Blood Diseases Hospital Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.